Rat Cysteinyl Leukotriene Receptor 2 (CYSLTR2) Protein

Product specifications

Proteins and Peptides

Cysteinyl Leukotriene Receptor 2 (CYSLTR2)

E. coli

Rat

Unconjugated

Concentration: Prior to lyophilization: 200 µg/ml
Sequence Fragment: Please enquire.
Tag: N-terminal His tag

Recombinant

> 90%

1 mg

5 mg

Lyophilized To keep the original salt concentration, we recommend reconstituting to the original concentration prior to lyophilization (see Concentration) in ddH2O. If a lower concentration is required, dilute in PBS, pH 7.4. If a higher concentration is required, the product can be reconstituted directly in PBS, pH 7.4, though please note that this will change the overall salt concentration. The stock concentration should be between 0.1-1.0 mg/ml. Do not vortex.

WB, SDS-PAGE

Prior to lyophilization: PBS, pH 7.4, containing 0.01% Sarcosyl, 1 mM DTT, 5% Trehalose and Proclin-300.

Shipped within 1-2 months.

Store at 2-8 °C for up to one month. Store at -80 °C for up to one year. Avoid repeated freeze/thaw cycles.

No

CYSLTR2,CYSLT2,CYSLT2R,GPCR21,HG57,HPN321,KPG_011,PSEC0146,hGPCR21,LTC4

Protein CYSLTR2

RUO

This product is for research use only.   Not for human consumption, cosmetic, therapeutic or diagnostic use.

Descripción

CYSLTR2 is a G protein-coupled receptor that binds cysteinyl leukotrienes, particularly LTC4 and LTD4, with a lower affinity for LTE4. CYSLTR2 is expressed in smooth muscle cells, endothelial cells, and immune cells, where it mediates inflammatory responses similar to CYSLTR1. CYSLTR2 activation leads to smooth muscle contraction, increased vascular permeability, and cytokine production through the phospholipase C (PLC)/calcium signaling pathway. While CYSLTR1 is more involved in acute bronchoconstriction, CYSLTR2 appears to play a complementary role in chronic inflammation, fibrosis, and tissue remodeling. Dysregulation of CYSLTR2 contributes to diseases such as asthma, pulmonary fibrosis, and cardiovascular conditions, where cysteinyl leukotriene signaling promotes tissue damage and chronic inflammation. Emerging evidence suggests CYSLTR2's involvement in cancer progression, particularly in promoting tumor-associated inflammation and angiogenesis. Targeting CYSLTR2, in combination with CYSLTR1 antagonists, is being explored to improve therapeutic outcomes in severe asthma, fibrosis, and inflammatory diseases.

Related Products

Human CYSLTR2 (Cysteinyl Leukotriene Receptor 2) ELISA Kit

Ver Producto

Rat CYSLTR2 (Cysteinyl Leukotriene Receptor 2) ELISA Kit

Ver Producto

Rat CYSLTR2 (Cysteinyl Leukotriene Receptor 2) QuickTest ELISA Kit

Ver Producto